Stocktoria
PAVmed Inc. PAVM
PAVmed Inc. (PAVM) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $71,000 at a 564.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PAVM | PAVmed Inc. | 3/9 | — | 90.2 | — |
| RDGL | VIVOS INC | 2/9 | — | — | — |
| GUTS | FRACTYL HEALTH, INC. | 2/9 | -16.47 | — | — |
| GIPL | Global Innovative Platforms Inc. | 3/9 | — | — | — |
| AMIX | Autonomix Medical, Inc. | 1/9 | — | — | — |
| ADGM | Adagio Medical Holdings, Inc. | 1/9 | -8.39 | — | — |
| SKYA | SkyAI, Inc. | 3/9 | — | — | — |
About PAVmed Inc.
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
FAQ
Is PAVM financially healthy?
PAVmed Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does PAVM pay a dividend?
No, PAVmed Inc. does not currently pay a dividend.
How profitable is PAVM?
In FY2025, PAVmed Inc. had a net margin of 564.8% and a return on equity of 1.2%.
What is PAVM's P/E ratio?
PAVmed Inc.'s trailing price-to-earnings (P/E) ratio is about 90.2×, based on its latest annual earnings.
What is the analyst price target for PAVM?
The average Wall-Street price target for PAVmed Inc. is $36.00, about 755.1% above the recent price, from 2 analysts.
Is PAVM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PAVmed Inc.: a Piotroski F-score of 3/9, a P/E of about 90.2×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.